{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T05:11:33Z","timestamp":1790831493886,"version":"4.1.0"},"reference-count":55,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2021,11,3]],"date-time":"2021-11-03T00:00:00Z","timestamp":1635897600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2021,11,3]],"date-time":"2021-11-03T00:00:00Z","timestamp":1635897600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100004472","name":"Riksbankens Jubileumsfond","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100004472","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100004359","name":"Vetenskapsr\u00e5det","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100004359","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Transl Psychiatry"],"abstract":"<jats:title>Abstract<\/jats:title><jats:p>It has been extensively debated whether selective serotonin reuptake inhibitors (SSRIs) are more efficacious than placebo in affective disorders, and it is not fully understood how SSRIs exert their beneficial effects. Along with serotonin transporter blockade, altered dopamine signaling and psychological factors may contribute. In this randomized clinical trial of participants with social anxiety disorder (SAD) we investigated how manipulation of verbally-induced expectancies, vital for placebo response, affect brain monoamine transporters and symptom improvement during SSRI treatment. Twenty-seven participants with SAD (17 men, 10 women), were randomized, to 9 weeks of overt or covert treatment with escitalopram 20\u2009mg. The overt group received correct treatment information whereas the covert group was treated deceptively with escitalopram, described as an active placebo in a cover story. Before and after treatment, patients underwent positron emission tomography (PET) assessments with the [<jats:sup>11<\/jats:sup>C]DASB and [<jats:sup>11<\/jats:sup>C]PE2I radiotracers, probing brain serotonin (SERT) and dopamine (DAT) transporters. SAD symptoms were measured by the Liebowitz Social Anxiety Scale. Overt was superior to covert SSRI treatment, resulting in almost a fourfold higher rate of responders. PET results showed that SERT occupancy after treatment was unrelated to anxiety reduction and equally high in both groups. In contrast, DAT binding decreased in the right putamen, pallidum, and the left thalamus with overt SSRI treatment, and increased with covert treatment, resulting in significant group differences. DAT binding potential changes in these regions correlated negatively with symptom improvement. Findings support that the anxiolytic effects of SSRIs involve psychological factors contingent on dopaminergic neurotransmission while serotonin transporter blockade alone is insufficient for clinical response.<\/jats:p>","DOI":"10.1038\/s41398-021-01682-3","type":"journal-article","created":{"date-parts":[[2021,11,3]],"date-time":"2021-11-03T08:06:41Z","timestamp":1635926801000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":45,"title":["Expectancy effects on serotonin and dopamine transporters during SSRI treatment of social anxiety disorder: a randomized clinical trial"],"prefix":"10.1038","volume":"11","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-4784-5196","authenticated-orcid":false,"given":"Olof R.","family":"Hjorth","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2516-9075","authenticated-orcid":false,"given":"Andreas","family":"Frick","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Malin","family":"Gingnell","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Johanna M.","family":"Hoppe","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vanda","family":"Faria","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sara","family":"Hultberg","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Iman","family":"Alaie","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kristoffer N. T.","family":"M\u00e5nsson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J\u00f6rgen","family":"Ros\u00e9n","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6041-0744","authenticated-orcid":false,"given":"Margareta","family":"Reis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kurt","family":"Wahlstedt","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"My","family":"Jonasson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mark","family":"Lubberink","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gunnar","family":"Antoni","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mats","family":"Fredrikson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6821-9058","authenticated-orcid":false,"given":"Tomas","family":"Furmark","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2021,11,3]]},"reference":[{"key":"1682_CR1","doi-asserted-by":"publisher","unstructured":"Kirsch I, Sapirstein G. Listening to Prozac but hearing placebo: a meta-analysis of antidepressant medication. Prev Treat. 1998;1. https:\/\/doi.org\/10.1037\/1522-3736.1.1.12a.","DOI":"10.1037\/1522-3736.1.1.12a"},{"key":"1682_CR2","doi-asserted-by":"publisher","first-page":"e45","DOI":"10.1371\/journal.pmed.0050045","volume":"5","author":"I Kirsch","year":"2008","unstructured":"Kirsch I, Deacon BJ, Huedo-Medina TB, Scoboria A, Moore TJ, Johnson BT. Initial severity and antidepressant benefits: a meta-analysis of data submitted to the Food and Drug Administration. PLoS Med. 2008;5:e45.","journal-title":"PLoS Med"},{"key":"1682_CR3","unstructured":"Kirsch I. The Emperor\u2019s New Drugs: Medication and Placebo in the Treatment of Depression. In: Benedetti F, Enck P, Frisaldi E, Schedlowski M, editors. Placebo. Handbook of Experimental Pharmacology. Berlin Heidelberg:Springer; 2014. p 291\u2013303."},{"key":"1682_CR4","doi-asserted-by":"publisher","first-page":"259","DOI":"10.1001\/archpsyc.1987.01800150071009","volume":"44","author":"FM Quitkin","year":"1987","unstructured":"Quitkin FM, Rabkin JD, Markowitz JM, Stewart JW, McGrath PJ, Harrison W. Use of pattern analysis to identify true drug response. A replication. Arch Gen Psychiatry. 1987;44:259\u201364.","journal-title":"Arch Gen Psychiatry"},{"key":"1682_CR5","doi-asserted-by":"publisher","first-page":"367","DOI":"10.1586\/14737175.2016.1155985","volume":"16","author":"T Bschor","year":"2016","unstructured":"Bschor T, Kilarski LL. Are antidepressants effective? A debate on their efficacy for the treatment of major depression in adults. Expert Rev Neurother. 2016;16:367\u201374.","journal-title":"Expert Rev Neurother"},{"key":"1682_CR6","doi-asserted-by":"publisher","first-page":"523","DOI":"10.1038\/mp.2015.53","volume":"21","author":"F Hieronymus","year":"2016","unstructured":"Hieronymus F, Emilsson JF, Nilsson S, Eriksson E. Consistent superiority of selective serotonin reuptake inhibitors over placebo in reducing depressed mood in patients with major depression. Mol Psychiatry. 2016;21:523\u201330.","journal-title":"Mol Psychiatry"},{"key":"1682_CR7","doi-asserted-by":"publisher","first-page":"e106337","DOI":"10.1371\/journal.pone.0106337","volume":"9","author":"MA Sugarman","year":"2014","unstructured":"Sugarman MA, Loree AM, Baltes BB, Grekin ER, Kirsch I. The Efficacy of Paroxetine and Placebo in Treating Anxiety and Depression: A Meta-Analysis of Change on the Hamilton Rating Scales. PLoS ONE. 2014;9:e106337.","journal-title":"PLoS ONE"},{"key":"1682_CR8","doi-asserted-by":"publisher","unstructured":"Kirsch I. Placebo Effect in the Treatment of Depression and Anxiety. Front Psychiatry 2019;10. https:\/\/doi.org\/10.3389\/fpsyt.2019.00407.","DOI":"10.3389\/fpsyt.2019.00407"},{"key":"1682_CR9","doi-asserted-by":"publisher","unstructured":"Faria V, Gingnell M, Hoppe JM, Hjorth O, Alaie I, Frick A, et al. Do You Believe It? Verbal Suggestions Influence the Clinical and Neural Effects of Escitalopram in Social Anxiety Disorder: a randomized trial. EBioMedicine.2017,24. https:\/\/doi.org\/10.1016\/j.ebiom.2017.09.031.","DOI":"10.1016\/j.ebiom.2017.09.031"},{"key":"1682_CR10","doi-asserted-by":"publisher","first-page":"368","DOI":"10.1016\/S2215-0366(14)70329-3","volume":"1","author":"E Mayo-Wilson","year":"2014","unstructured":"Mayo-Wilson E, Dias S, Mavranezouli I, Kew K, Clark DM, Ades AE, et al. Psychological and pharmacological interventions for social anxiety disorder in adults: a systematic review and network meta-analysis. lancet Psychiatry. 2014;1:368\u201376.","journal-title":"lancet Psychiatry"},{"key":"1682_CR11","doi-asserted-by":"publisher","first-page":"1357","DOI":"10.1016\/S0140-6736(17)32802-7","volume":"391","author":"A Cipriani","year":"2018","unstructured":"Cipriani A, Furukawa TA, Salanti G, Chaimani A, Atkinson LZ, Ogawa Y, et al. Comparative efficacy and acceptability of 21 antidepressant drugs for the acute treatment of adults with major depressive disorder: a systematic review and network meta-analysis. Lancet. 2018;391:1357\u201366.","journal-title":"Lancet"},{"key":"1682_CR12","doi-asserted-by":"publisher","first-page":"733","DOI":"10.1016\/S0006-3223(00)00832-5","volume":"47","author":"I Kirsch","year":"2000","unstructured":"Kirsch I. Are drug and placebo effects in depression additive? Biol Psychiatry. 2000;47:733\u20135.","journal-title":"Biol Psychiatry"},{"key":"1682_CR13","doi-asserted-by":"publisher","first-page":"1731","DOI":"10.1038\/mp.2017.147","volume":"23","author":"F Hieronymus","year":"2018","unstructured":"Hieronymus F, Lisinski A, Nilsson S, Eriksson E. Efficacy of selective serotonin reuptake inhibitors in the absence of side effects: a mega-analysis of citalopram and paroxetine in adult depression. Mol Psychiatry. 2018;23:1731\u20136.","journal-title":"Mol Psychiatry"},{"key":"1682_CR14","doi-asserted-by":"publisher","first-page":"679","DOI":"10.1016\/S1474-4422(04)00908-1","volume":"3","author":"L Colloca","year":"2004","unstructured":"Colloca L, Lopiano L, Lanotte M, Benedetti F. Overt versus covert treatment for pain, anxiety, and Parkinson\u2019s disease. Lancet Neurol. 2004;3:679\u201384.","journal-title":"Lancet Neurol"},{"key":"1682_CR15","doi-asserted-by":"publisher","first-page":"70ra14","DOI":"10.1126\/scitranslmed.3001244","volume":"3","author":"U Bingel","year":"2011","unstructured":"Bingel U, Wanigasekera V, Wiech K, Ni Mhuircheartaigh R, Lee MC, Ploner M, et al. The Effect of Treatment Expectation on Drug Efficacy: Imaging the Analgesic Benefit of the Opioid Remifentanil. Sci Transl Med. 2011;3:70ra14\u201370ra14.","journal-title":"Sci Transl Med"},{"key":"1682_CR16","doi-asserted-by":"publisher","DOI":"10.1186\/1471-2288-11-90","volume":"11","author":"P Enck","year":"2011","unstructured":"Enck P, Klosterhalfen S, Zipfel S. Novel study designs to investigate the placebo response. BMC Med Res Methodol. 2011;11:90.","journal-title":"BMC Med Res Methodol"},{"key":"1682_CR17","doi-asserted-by":"publisher","first-page":"11461","DOI":"10.1523\/JNEUROSCI.23-36-11461.2003","volume":"23","author":"ND Volkow","year":"2003","unstructured":"Volkow ND, Wang GJ, Ma Y, Fowler JS, Zhu W, Maynard L, et al. Expectation Enhances the Regional Brain Metabolic and the Reinforcing Effects of Stimulants in Cocaine Abusers. J Neurosci. 2003;23:11461\u20138.","journal-title":"J Neurosci"},{"key":"1682_CR18","doi-asserted-by":"publisher","first-page":"1782","DOI":"10.1016\/j.neuroimage.2006.04.192","volume":"32","author":"ND Volkow","year":"2006","unstructured":"Volkow ND, Wang GJ, Ma Y, Fowler JS, Wong C, Jayne M, et al. Effects of expectation on the brain metabolic responses to methylphenidate and to its placebo in non-drug abusing subjects. Neuroimage. 2006;32:1782\u201392.","journal-title":"Neuroimage"},{"key":"1682_CR19","doi-asserted-by":"publisher","first-page":"11","DOI":"10.1016\/S0163-7258(99)00048-0","volume":"85","author":"C Hiemke","year":"2000","unstructured":"Hiemke C, H\u00e4rtter S. Pharmacokinetics of selective serotonin reuptake inhibitors. Pharm Ther. 2000;85:11\u201328.","journal-title":"Pharm Ther"},{"key":"1682_CR20","doi-asserted-by":"publisher","first-page":"826","DOI":"10.1176\/appi.ajp.161.5.826","volume":"161","author":"JH Meyer","year":"2004","unstructured":"Meyer JH, Wilson AA, Sagrati S, Hussey D, Carella A, Potter WZ, et al. Serotonin transporter occupancy of five selective serotonin reuptake inhibitors at different doses: an [11C]DASB positron emission tomography study. Am J Psychiatry. 2004;161:826\u201335.","journal-title":"Am J Psychiatry"},{"key":"1682_CR21","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1016\/S0079-6123(08)00901-1","volume":"172","author":"E Esposito","year":"2008","unstructured":"Esposito E, Di Matteo V, Di Giovanni G. Serotonin-dopamine interaction: an overview. Prog Brain Res. 2008;172:3\u20136.","journal-title":"Prog Brain Res"},{"key":"1682_CR22","doi-asserted-by":"publisher","first-page":"89","DOI":"10.1016\/j.pharmthera.2008.10.004","volume":"121","author":"LC Daws","year":"2009","unstructured":"Daws LC. Unfaithful neurotransmitter transporters: focus on serotonin uptake and implications for antidepressant efficacy. Pharm Ther. 2009;121:89\u201399.","journal-title":"Pharm Ther"},{"key":"1682_CR23","doi-asserted-by":"publisher","unstructured":"Hjorth OR, Frick A, Gingnell M, Hoppe JM, Faria V, Hultberg S, et al. Expression and co-expression of serotonin and dopamine transporters in social anxiety disorder: a multitracer positron emission tomography study. Mol Psychiatry. 2019. https:\/\/doi.org\/10.1038\/s41380-019-0618-7.","DOI":"10.1038\/s41380-019-0618-7"},{"key":"1682_CR24","doi-asserted-by":"publisher","first-page":"413","DOI":"10.1038\/sj.npp.1300036","volume":"28","author":"A Kugaya","year":"2003","unstructured":"Kugaya A, Seneca NM, Snyder PJ, Williams SA, Malison RT, Baldwin RM, et al. Changes in human in vivo serotonin and dopamine transporter availabilities during chronic antidepressant administration. Neuropsychopharmacology. 2003;28:413\u201320.","journal-title":"Neuropsychopharmacology"},{"key":"1682_CR25","doi-asserted-by":"publisher","first-page":"996","DOI":"10.1038\/sj.npp.1300683","volume":"30","author":"MM de Win","year":"2005","unstructured":"de Win MM, Habraken JB, Reneman L, van den Brink W, den Heeten GJ, Booij J. Validation of [123I]\u03b2-CIT SPECT to Assess Serotonin Transporters In Vivo in Humans: a Double-Blind, Placebo-Controlled, Crossover Study with the Selective Serotonin Reuptake Inhibitor Citalopram. Neuropsychopharmacology. 2005;30:996\u20131005.","journal-title":"Neuropsychopharmacology"},{"key":"1682_CR26","doi-asserted-by":"publisher","first-page":"521","DOI":"10.1016\/j.euroneuro.2005.01.003","volume":"15","author":"O Pogarell","year":"2005","unstructured":"Pogarell O, Poepperl G, Mulert C, Hamann C, Sadowsky N, Riedel M, et al. SERT and DAT availabilities under citalopram treatment in obsessive-compulsive disorder (OCD). Eur Neuropsychopharmacol. 2005;15:521\u20134.","journal-title":"Eur Neuropsychopharmacol"},{"key":"1682_CR27","doi-asserted-by":"publisher","first-page":"151","DOI":"10.1007\/s11011-012-9280-3","volume":"27","author":"JM Warwick","year":"2012","unstructured":"Warwick JM, Carey PD, Cassimjee N, Lochner C, Hemmings S, Moolman-Smook H, et al. Dopamine transporter binding in social anxiety disorder: the effect of treatment with escitalopram. Metab Brain Dis. 2012;27:151\u20138.","journal-title":"Metab Brain Dis"},{"key":"1682_CR28","doi-asserted-by":"publisher","first-page":"873","DOI":"10.1016\/j.euroneuro.2014.12.010","volume":"25","author":"A Rominger","year":"2015","unstructured":"Rominger A, Cumming P, Brendel M, Xiong G, Zach C, Karch S. et al. Altered serotonin and dopamine transporter availabilities in brain of depressed patients upon treatment with escitalopram: a [123I]$\u03b2$-CIT SPECT study. Eur Neuropsychopharmacol. 2015;25:873\u201381.","journal-title":"Eur Neuropsychopharmacol"},{"key":"1682_CR29","doi-asserted-by":"publisher","unstructured":"Diagnostic and Statistical Manual of Mental Disorders, Fourth Edition, Text Revision (DSM-IV-TR). 4th editio. American Psychiatric Association: Arlington, VA, 2000 https:\/\/doi.org\/10.1176\/appi.books.9780890423349.","DOI":"10.1176\/appi.books.9780890423349"},{"key":"1682_CR30","first-page":"22","volume":"59","author":"DV Sheehan","year":"1998","unstructured":"Sheehan DV, Lecrubier Y, Sheehan KH, Amorim P, Janavs J, Weiller E, et al. The Mini-International Neuropsychiatric Interview (M.I.N.I.): the development and validation of a structured diagnostic psychiatric interview for DSM-IV and ICD-10. J Clin Psychiatry. 1998;59:22\u201333;quiz 34-57. Suppl 2","journal-title":"J Clin Psychiatry"},{"key":"1682_CR31","doi-asserted-by":"publisher","first-page":"141","DOI":"10.1159\/000414022","volume":"22","author":"MR Liebowitz","year":"1987","unstructured":"Liebowitz MR. Social phobia. Mod Probl Pharmacopsychiatry. 1987;22:141\u201373.","journal-title":"Mod Probl Pharmacopsychiatry"},{"key":"1682_CR32","doi-asserted-by":"publisher","first-page":"834","DOI":"10.1097\/00004647-199609000-00008","volume":"16","author":"J Logan","year":"1996","unstructured":"Logan J, Fowler JS, Volkow ND, Wang GJ, Ding YS, Alexoff DL. Distribution Volume Ratios without Blood Sampling from Graphical Analysis of PET Data. J Cereb Blood Flow Metab. 1996;16:834\u201340.","journal-title":"J Cereb Blood Flow Metab"},{"key":"1682_CR33","doi-asserted-by":"publisher","first-page":"279","DOI":"10.1006\/nimg.1997.0303","volume":"6","author":"RN Gunn","year":"1997","unstructured":"Gunn RN, Lammertsma AA, Hume SP, Cunningham VJ. Parametric Imaging of Ligand-Receptor Binding in PET Using a Simplified Reference Region Model. Neuroimage. 1997;6:279\u201387.","journal-title":"Neuroimage"},{"key":"1682_CR34","doi-asserted-by":"publisher","first-page":"969","DOI":"10.1016\/j.neuroimage.2004.10.017","volume":"24","author":"C Svarer","year":"2005","unstructured":"Svarer C, Madsen K, Hasselbalch SG, Pinborg LH, Haugb\u00f8l S, Fr\u00f8kjaer VG, et al. MR-based automatic delineation of volumes of interest in human brain PET images using probability maps. Neuroimage. 2005;24:969\u201379.","journal-title":"Neuroimage"},{"key":"1682_CR35","doi-asserted-by":"publisher","first-page":"12","DOI":"10.1037\/0022-006X.59.1.12","volume":"59","author":"NS Jacobson","year":"1991","unstructured":"Jacobson NS, Truax P. Clinical significance: a statistical approach to defining meaningful change in psychotherapy research. J Consult Clin Psychol. 1991;59:12\u20139.","journal-title":"J Consult Clin Psychol"},{"key":"1682_CR36","doi-asserted-by":"publisher","first-page":"1233","DOI":"10.1016\/S1053-8119(03)00169-1","volume":"19","author":"JA Maldjian","year":"2003","unstructured":"Maldjian JA, Laurienti PJ, Kraft RA, Burdette JH. An automated method for neuroanatomic and cytoarchitectonic atlas-based interrogation of fMRI data sets. Neuroimage. 2003;19:1233\u20139.","journal-title":"Neuroimage"},{"key":"1682_CR37","doi-asserted-by":"publisher","first-page":"224","DOI":"10.1002\/hbm.10123","volume":"19","author":"A Hammers","year":"2003","unstructured":"Hammers A, Allom R, Koepp MJ, Free SL, Myers R, Lemieux L, et al. Three-dimensional maximum probability atlas of the human brain, with particular reference to the temporal lobe. Hum Brain Mapp. 2003;19:224\u201347.","journal-title":"Hum Brain Mapp"},{"key":"1682_CR38","doi-asserted-by":"publisher","first-page":"1885","DOI":"10.2967\/jnumed.110.078337","volume":"51","author":"M Ziebell","year":"2010","unstructured":"Ziebell M, Holm-Hansen S, Thomsen G, Wagner A, Jensen P, Pinborg LH, et al. Serotonin Transporters in Dopamine Transporter Imaging: A Head-to-Head Comparison of Dopamine Transporter SPECT Radioligands 123I-FP-CIT and 123I-PE2I. J Nucl Med. 2010;51:1885\u201391.","journal-title":"J Nucl Med"},{"key":"1682_CR39","doi-asserted-by":"publisher","first-page":"709","DOI":"10.1177\/0269881108098144","volume":"24","author":"SD Hood","year":"2010","unstructured":"Hood SD, Potokar JP, Davies SJ, Hince DA, Morris K, Seddon KM, et al. Dopaminergic challenges in social anxiety disorder: evidence for dopamine D 3 desensitisation following successful treatment with serotonergic antidepressants. J Psychopharmacol. 2010;24:709\u201316.","journal-title":"J Psychopharmacol"},{"key":"1682_CR40","doi-asserted-by":"publisher","first-page":"1064","DOI":"10.4088\/JCP.v65n0806","volume":"65","author":"C Damsa","year":"2004","unstructured":"Damsa C, Bumb A, Bianchi-Demicheli F, Vidailhet P, Sterck R, Andreoli A, et al. \u2018Dopamine-dependent\u2019 side effects of selective serotonin reuptake inhibitors: a clinical review. J Clin Psychiatry. 2004;65:1064\u20138.","journal-title":"J Clin Psychiatry"},{"key":"1682_CR41","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/0014-2999(91)90658-D","volume":"200","author":"S Benloucif","year":"1991","unstructured":"Benloucif S, Galloway MP. Facilitation of dopamine release in vivo by serotonin agonists: studies with microdialysis. Eur J Pharm. 1991;200:1\u20138.","journal-title":"Eur J Pharm"},{"key":"1682_CR42","doi-asserted-by":"publisher","first-page":"949","DOI":"10.1016\/S0893-133X(02)00377-9","volume":"27","author":"S Koch","year":"2002","unstructured":"Koch S, Perry KW, Nelson DL, Conway RG, Threlkeld PG, Bymaster FP. R-fluoxetine increases extracellular DA, NE, as well as 5-HT in rat prefrontal cortex and hypothalamus: an in vivo microdialysis and receptor binding study. Neuropsychopharmacology. 2002;27:949\u201359.","journal-title":"Neuropsychopharmacology"},{"key":"1682_CR43","doi-asserted-by":"publisher","first-page":"187","DOI":"10.1016\/j.euroneuro.2006.04.006","volume":"17","author":"F Chenu","year":"2007","unstructured":"Chenu F, Dailly E, Bourin M. Effect of antidepressant drugs on 6-OHDA-treated mice in the FST. Eur Neuropsychopharmacol. 2007;17:187\u201393.","journal-title":"Eur Neuropsychopharmacol"},{"key":"1682_CR44","doi-asserted-by":"publisher","first-page":"65","DOI":"10.1016\/j.neuron.2005.02.010","volume":"46","author":"F-M Zhou","year":"2005","unstructured":"Zhou F-M, Liang Y, Salas R, Zhang L, De Biasi M, Dani JA. Corelease of Dopamine and Serotonin from Striatal Dopamine Terminals. Neuron. 2005;46:65\u201374.","journal-title":"Neuron"},{"key":"1682_CR45","doi-asserted-by":"publisher","first-page":"7","DOI":"10.31887\/DCNS.2016.18.1\/shaber","volume":"18","author":"SN Haber","year":"2016","unstructured":"Haber SN. Corticostriatal circuitry. Dialogues Clin Neurosci. 2016;18:7\u201321.","journal-title":"Dialogues Clin Neurosci"},{"key":"1682_CR46","doi-asserted-by":"publisher","first-page":"679","DOI":"10.1007\/s00702-016-1510-0","volume":"123","author":"W Schultz","year":"2016","unstructured":"Schultz W. Reward functions of the basal ganglia. J Neural Transm. 2016;123:679\u201393.","journal-title":"J Neural Transm"},{"key":"1682_CR47","doi-asserted-by":"publisher","first-page":"220","DOI":"10.1001\/archgenpsychiatry.2007.34","volume":"65","author":"DJ Scott","year":"2008","unstructured":"Scott DJ, Stohler CS, Egnatuk CM, Wang H, Koeppe RA, Zubieta JK. Placebo and Nocebo Effects Are Defined by Opposite Opioid and Dopaminergic Responses. Arch Gen Psychiatry. 2008;65:220\u201331.","journal-title":"Arch Gen Psychiatry"},{"key":"1682_CR48","doi-asserted-by":"publisher","first-page":"79","DOI":"10.1016\/j.neubiorev.2011.04.012","volume":"36","author":"S Cabib","year":"2012","unstructured":"Cabib S, Puglisi-Allegra S. The mesoaccumbens dopamine in coping with stress. Neurosci Biobehav Rev. 2012;36:79\u201389.","journal-title":"Neurosci Biobehav Rev"},{"key":"1682_CR49","doi-asserted-by":"publisher","first-page":"189","DOI":"10.1111\/psyg.12014","volume":"13","author":"H Hori","year":"2013","unstructured":"Hori H, Kunugi H. Dopamine agonist-responsive depression. Psychogeriatrics. 2013;13:189\u201395.","journal-title":"Psychogeriatrics"},{"key":"1682_CR50","doi-asserted-by":"publisher","first-page":"794","DOI":"10.1001\/jamapsychiatry.2015.0125","volume":"72","author":"A Frick","year":"2015","unstructured":"Frick A, \u00c5hs F, Engman J, Jonasson M, Alaie I, Bj\u00f6rkstrand J, et al. Serotonin synthesis and reuptake in social anxiety disorder a positron emission tomography study. JAMA Psychiatry. 2015;72:794\u2013802.","journal-title":"JAMA Psychiatry"},{"key":"1682_CR51","doi-asserted-by":"publisher","first-page":"301","DOI":"10.1016\/j.biopsych.2005.06.029","volume":"59","author":"J Cavanagh","year":"2006","unstructured":"Cavanagh J, Patterson J, Pimlott S, Dewar D, Eersels J, Dempsey MF, et al. Serotonin transporter residual availability during long-term antidepressant therapy does not differentiate responder and nonresponder unipolar patients. Biol Psychiatry. 2006;59:301\u20138.","journal-title":"Biol Psychiatry"},{"key":"1682_CR52","doi-asserted-by":"publisher","first-page":"659","DOI":"10.1007\/s00702-005-0429-7","volume":"113","author":"N Herold","year":"2006","unstructured":"Herold N, Uebelhack K, Franke L, Amthauer H, Luedemann L, Bruhn H, et al. Imaging of serotonin transporters and its blockade by citalopram in patients with major depression using a novel SPECT ligand [123I]-ADAM. J Neural Transm. 2006;113:659\u201370.","journal-title":"J Neural Transm"},{"key":"1682_CR53","doi-asserted-by":"publisher","first-page":"252","DOI":"10.1016\/j.neuroimage.2013.10.002","volume":"88","author":"P Baldinger","year":"2014","unstructured":"Baldinger P, Kranz GS, Haeusler D, Savli M, Spies M, Philippe C, et al. Regional differences in SERT occupancy after acute and prolonged SSRI intake investigated by brain PET. Neuroimage. 2014;88:252\u201362.","journal-title":"Neuroimage"},{"key":"1682_CR54","doi-asserted-by":"publisher","first-page":"503","DOI":"10.1016\/j.biopsych.2004.07.006","volume":"56","author":"SV Argyropoulos","year":"2004","unstructured":"Argyropoulos SV, Hood SD, Adrover M, Bell CJ, Rich AS, Nash JR, et al. Tryptophan depletion reverses the therapeutic effect of selective serotonin reuptake inhibitors in social anxiety disorder. Biol Psychiatry. 2004;56:503\u20139.","journal-title":"Biol Psychiatry"},{"key":"1682_CR55","doi-asserted-by":"publisher","first-page":"1775","DOI":"10.1016\/j.euroneuro.2016.09.004","volume":"26","author":"A Frick","year":"2016","unstructured":"Frick A, \u00c5hs F, Appel L, Jonasson M, Wahlstedt K, Bani M, et al. Reduced serotonin synthesis and regional cerebral blood flow after anxiolytic treatment of social anxiety disorder. Eur Neuropsychopharmacol. 2016;26:1775\u201383.","journal-title":"Eur Neuropsychopharmacol"}],"container-title":["Translational Psychiatry"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41398-021-01682-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41398-021-01682-3","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41398-021-01682-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,12,1]],"date-time":"2022-12-01T15:27:31Z","timestamp":1669908451000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41398-021-01682-3"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,11,3]]},"references-count":55,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2021,12]]}},"alternative-id":["1682"],"URL":"https:\/\/doi.org\/10.1038\/s41398-021-01682-3","relation":{},"ISSN":["2158-3188"],"issn-type":[{"value":"2158-3188","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,11,3]]},"assertion":[{"value":"31 March 2021","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"14 September 2021","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"19 October 2021","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"3 November 2021","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no competing interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"559"}}